Recent updates in renal cell carcinoma

Current Opinion in Oncology

Volumn 22, Issue 3, 2010, Pages 250-256

  Rathmell, W Kimryn ^a   Godley, Paul A ^a  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

Birt Hogg Dube; Hypoxia inducible factor; Mammalian target of rapamycin; Renal cell carcinoma; Tyrosine kinase inhibitor; Vascular endothelial growth factor; Von Hippel Lindau

Indexed keywords

BEVACIZUMAB; HYPOXIA INDUCIBLE FACTOR 1; HYPOXIA INDUCIBLE FACTOR 2ALPHA; INTERFERON; MAMMALIAN TARGET OF RAPAMYCIN; SORAFENIB; SUNITINIB; TEMSIROLIMUS; VASCULOTROPIN; VASCULOTROPIN INHIBITOR; VON HIPPEL LINDAU PROTEIN;

CANCER DIAGNOSIS; CANCER GENETICS; CANCER INCIDENCE; CANCER LOCALIZATION; CARCINOGENESIS; CLEAR CELL CARCINOMA; CORRELATION ANALYSIS; DISEASE FREE SURVIVAL; DRUG ACTIVITY; EPIDEMIOLOGICAL DATA; FEMALE; GENE LOSS; GENETIC ANALYSIS; HEREDITY; HISTOPATHOLOGY; HUMAN; KIDNEY CARCINOMA; MALE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RECURRENCE RISK; REVIEW; RISK FACTOR; SIGNAL TRANSDUCTION;

CARCINOMA, RENAL CELL; CHEMOTHERAPY, ADJUVANT; DRUG DELIVERY SYSTEMS; HUMANS; KIDNEY NEOPLASMS; NEOADJUVANT THERAPY; NEPHRECTOMY;

EID: 77951474910     PISSN: 10408746     EISSN: None     Source Type: Journal    
DOI: 10.1097/CCO.0b013e328337a5d2     Document Type: Review

References (38)

1. Cancer Facts and Figures 2009. American Cancer Society, Inc.
2. Gordan JD, Lal P, Dondeti VR, et al. HIF-alpha effects on c-Myc distinguish two subtypes of sporadic VHL-deficient clear cell renal carcinoma. Cancer Cell 2008; 14:435-446.
3. Beroukhim R, Brunet JP, Di Napoli A, et al. Patterns of gene expression and copy-number alterations in von-hippel lindau disease-associated and sporadic clear cell carcinoma of the kidney. Cancer Res 2009; 69:4674-4681.
4. Klatte T, Rao PN, de Martino M, et al. Cytogenetic profile predicts prognosis of patients with clear cell renal cell carcinoma. J Clin Oncol 2009; 27:746-753.
5. Nickerson ML, Warren MB, Toro JR, et al. Mutations in a novel gene lead to kidney tumors, lung wall defects, and benign tumors of the hair follicle in patients with the Birt-Hogg-Dube syndrome. Cancer Cell 2002; 2:157-164.
6. Hartman TR, Nicolas E, Klein-Szanto A, et al. The role of the Birt-Hogg-Dube protein in mTOR activation and renal tumorigenesis. Oncogene 2009; 28:1594-1604.
7. Hasumi Y, Baba M, Ajima R, et al. Homozygous loss of BHD causes early embryonic lethality and kidney tumor development with activation of mTORC1 and mTORC2. Proc Natl Acad Sci USA 2009; 106:18722-18727.
8. Lee CM, Hickey MM, Sanford CA, et al. VHL Type 2B gene mutation moderates HIF dosage in vitro and in vivo. Oncogene 2009; 28:1694-1705.
9. Linguraru MG, Yao J, Gautam R, et al. Renal tumor quantification and classification in contrast-enhanced abdominal CT. Pattern Recognit 2009; 42:1149-1161.
10. van der Veldt AAM, MeijerinkMR,van den Eertwegh AJM, etal. Choi response criteria for early prediction of clinical outcome in patients with metastatic renal cell cancer treated with sunitinib. Am J Roentgenogr (in press).
11. Cowey CL, Fielding JR, Rathmell WK. The loss of radiographic enhancement in primary renal cell carcinoma tumors following multitargeted receptor tyrosine kinase therapy is an additional indicator of response. Urology 2009 [Epub ahead of print].
12. Boris R, Proano M, Linehan WM, et al. Initial experience with robot assisted partial nephrectomy for multiple renal masses. J Urol 2009; 182:1280-1286.
13. Chen DY, Uzzo RG. Optimal management of localized renal cell carcinoma: surgery, ablation, or active surveillance. J Natl Compr Canc Netw 2009; 7:635-642; quiz 643.
14. Messing EM, Manola J, Wilding G, etal. Phase III study of interferon alfa-NLas adjuvant treatment for resectable renal cell carcinoma: an Eastern Cooperative Oncology Group/Intergroup trial. J Clin Oncol 2003; 21:1214-1222.
15. ClarkJI, Atkins MB, Urba WJ, etal. Adjuvant high-dose bolus interleukin-2 for patients with high-risk renal cell carcinoma: a cytokine working group randomized trial. J Clin Oncol 2003; 21:3133-3140.
16. May M, Brookman-May S, Hoschke B, etal. Ten-year survival analysis for renal carcinoma patients treated with an autologous tumour lysate vaccine in an adjuvant setting. Cancer Immunol Immunother 2009 [Epub ahead of print].
17. Margulis V, Matin SF, Tannir N, etal. Randomized trial of adjuvant thalidomide versus observation in patients with completely resected high-risk renal cell carcinoma. Urology 2009; 73:337-341.
18. Leibovich BC, Cheville JC, Lohse CM, et al. A scoring algorithm to predict survival for patients with metastatic clear cell renal cell carcinoma: a stratification tool for prospective clinical trials. J Urol 2005; 174:1759-1763; discussion 1763.
19. Jonasch E, Wood CG, Matin SF, etal. Phase II presurgical feasibility study of bevacizumab in untreated patients with metastatic renal cell carcinoma. J Clin Oncol 2009; 27:4076-4081.
20. Thomas AA, Rini BI, Stephenson AJ, et al. Surgical resection of renal cell carcinoma after targeted therapy. J Urol 2009; 182:881-886.
21. Amin C, Wallen E, Pruthi RS, et al. Preoperative tyrosine kinase inhibition as an adjunct to debulking nephrectomy. Urology 2008; 72:864-868.
22. Thomas AA, Rini BI, Lane BR, et al. Response of the primary tumor to neoadjuvant sunitinib in patients with advanced renal cell carcinoma. J Urol 2009; 181:518-523; discussion 523.
23. CoweyCL, Amin C, Pruthi RS, et al. A neoadjuvant clinical trial with sorafenibfor patients with stage II or greater renal cell carcinoma. J Clin Oncol (in press).
24. Di Lorenzo G, Autorino R, Bruni G, et al. Cardiovascular toxicity following sunitinib therapy in metastatic renal cell carcinoma: a multicenter analysis. Ann Oncol 2009; 20:1535-1542.
25. Chintalgattu V, Patel SS, Khakoo AY. Cardiovascular effects of tyrosine kinase inhibitors used for gastrointestinal stromal tumors. Hematol Oncol Clin North Am 2009; 23:97-107; viii-ix.
26. Cho DC, Puzanov I, Regan MM, et al. Retrospective analysis of the safety and efficacy of interleukin-2 after prior VEGF-targeted therapy in patients with advanced renal cell carcinoma. J Immunother 2009; 32:181-185.
27. Shepard DR, Garcia JA. Toxicity associated with the long-term use of targeted therapies in patients with advanced renal cell carcinoma. Expert Rev Anticancer Ther 2009; 9:795-805.
28. Robert C, Mateus C, Spatz A, et al. Dermatologic symptoms associated with the multikinase inhibitor sorafenib. J Am Acad Dermatol 2009; 60:299-305.
29. Motzer RJ, Hutson TE, Tomczak P, et al. Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J Clin Oncol 2009; 27:3584-3590.
30. Rini BI, Atkins MB. Resistance to targeted therapy in renal-cell carcinoma. Lancet Oncol 2009; 10:992-1000.
31. Panka D, Kumar M, Schor-Bardach R, Atkins M. Mechanism of acquired resistance to sorafenib in RCC. In AACR proceedings. 2008. pp. 2500.
32. Bhatia S, Thompson JA. Temsirolimus in patients with advanced renal cell carcinoma: an overview. Adv Ther 2009; 26:55-67.
33. Motzer RJ, Escudier B, Oudard S, et al. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet 2008; 372:449-456.
34. Oudard S, Medioni J, Aylllon J, et al. Everolimus (RAD001):an mTOR inhibitor for the treatment of metastatic renal cell carcinoma. Expert Rev Anticancer Ther 2009; 9:705-717.
35. Sosman JA, Puzanov I, Atkins MB. Opportunities and obstacles to combination targeted therapy in renal cell cancer. Clin Cancer Res 2007; 13:764s-769s.
36. Sosman J, Puzanov I. Combination targeted therapy in advanced renal cell carcinoma. Cancer 2009; 115:2368-2375.
37. Fischer P, Patel P, Carducci MA, etal. Phase I study combining treatment with temsirolimus and sunitinib malate in patients with advanced renal cell carci-nomaP. ASCO Annual Meeting Proc 2008; 26:16020.
38. Clinical Recommendations. NCCN clinical practice guidelines in oncology. Kidney cancer. J Natl Compr Canc Netw 2009; 7.